Javi del Cid (@javidlcid) profile picture

•Physician •Internal Medicine •Ex becario Ruta Quetzal

Barcelona, España
Joined May 2011
🔴Nuevo número (nov. 2026) de #RevistaNefrología ya disponible para vuestra lectura👇 🔴Artículo Especial: Documento de consenso en el diagnóstico y tratamiento de las alteraciones metabólicas en la enfermedad litiásica urinaria @juanmbuadesfust @aortznfr @ramos_cebrian revistanefrologia.com/es-doc…
21
51
1,932
Javi del Cid retweeted
The 2026 BSR Guideline for the diagnosis and management of systemic autoimmune rheumatic disease associated interstitial lung disease [SARD-ILD]
2
44
97
3,992
Javi del Cid retweeted
IgG4-RD ➡️ Rare, heterogeneous disease (4 phenotypes; male:female 3:1). Exclude malignancy, infection and inflammatory mimics before diagnosis. Cancer risk remains uncertain. Limit cumulative GC exposure; consider baseline whole-body imaging case by case. #ACR26
1
47
102
4,215
🆕 Clinical Year in Review at #ACR26 By Dr. Liana Fraenkel @YaleRheumAller1 💡Review the most impactful #rheum studies and trials from the past year! ❓Any studies you would add to the list? #RheumX #RheumTwitter #ACR2026
1
46
2
114
16,037
🔥Hot off the press for #ACR26 🔥 The @IgG4ward foundation guidelines on the treatment of IgG4-related disease thelancet.com/journals/lanrh… Free to read on lancet.com
117
3
292
19,619
Javi del Cid retweeted
✅ Are you a MEDICAL DOCTOR taking care of #LUPUS? We are trying to map availability and accessibility of #SLE treatments in EVERY COUNTRY OF THE WORLD (check the map of participants) 🌍🌎🌏 and help us by filling-in our #STRIDE study 🙏🔄 LINK to study:lupusresearch.limequery.org/…
3
27
3
66
5,203
Javi del Cid retweeted
Original Article: Ianalumab for the Treatment of Patients with Sjögren’s Disease (phase 3 NEPTUNUS-1 and NEPTUNUS-2 trials) nej.md/3VU4TAp Editorial: Ianalumab in Sjögren’s Disease — A First Step nej.md/4ivvs7E #Rheumatology #Immunology
20
60
14,975
Javi del Cid retweeted
The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica #Rheumatology
1
33
69
3,221
Javi del Cid retweeted
A 69-year-old woman presented with 4-year history of recurrent cough, exertional dyspnea, and intermittent throat tightness. Nine months before admission, she developed arthralgia in her knees & ankles and painful bilateral auricular swelling (A), followed by flaccid auricular deformity (B) Clinical images in ACROR doi.org/10.1002/acr2.90166
5
18
2
44
4,816
Javi del Cid retweeted
Comparing tumor necrosis factor inhibitors (TNFi) and tocilizumab (TCZ) on Takayasu arteritis (n=151) showed similar overall effectiveness. Age at symptom onset was associated with differential biologic response, with younger-onset disease favoring TNFi response, and older-onset disease favoring TCZ response AC&R doi.org/10.1002/acr.80169
22
4
60
4,579
Javi del Cid retweeted
First case report of BCMA-directed CAR-T therapy for severe, refractory antiphospholipid syndrome. The patient had triple-positive APS with recurrent, life-threatening diffuse alveolar hemorrhage despite rituximab and high-dose GCs. BCMA CAR-T therapy resulted in a rapid clinical response, elimination of antiphospholipid antibodies, and sustained remission at 6 months A&R doi.org/10.1002/art.70322
21
1
41
2,924
Javi del Cid retweeted
📝 #JAMAReview: #LiquidBiopsy using circulating #tumor #DNA can help guide care in #Cancer by identifying gene variants associated with treatment selection, monitoring treatment response, and detecting minimal residual disease after therapy. Detectable circulating tumor DNA after curative-intent treatment was associated with recurrence and poorer survival across multiple cancer settings, often before progression was evident on imaging. ja.ma/4dFgtVU
9
130
6
391
26,219
New England Journal of Medicine (NEJM) 2026: Terapia actual para mieloma múltiple DOI:10.1056/NEJMra2605253 #MedEd #MedTwitter #MedX medicina-interna.org
49
1
176
4,277
Javi del Cid retweeted
Original Article: Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy (phase 3 MAJESTY trial) nej.md/4dZsVPD Editorial: A Step Forward — Obinutuzumab for Membranous Nephropathy nej.md/4xEuzyS #Nephrology
1
28
1
85
35,394
🚨 The revised #SLICC #damage index (#SDI) for #lupus has been published!!! 💥 Kudos @fizyobrk & Ian Bruce for leading the way 📥 DOWNLOAD link: doi.org/10.1002/acr.80102
2
49
1
123
6,636
Javi del Cid retweeted
Behçet’s syndrome remains rare in England—but its prevalence is rising. A 21-year UK real-world study found: 🔹 Incidence remained stable (~0.75/100,000 person-years) 🔹 Prevalence nearly doubled (8.6 → 19.8/100,000) 🔹 Genital ulcers were the strongest clinical clue for earlier diagnosis 🔹 Oral ulcers, uveitis and Crohn’s disease were strongly associated with BS Earlier recognition could help reduce diagnostic delay 🔗 rmdopen.bmj.com/content/12/3… #Behçets #Vasculitis #Rheumatology #RareDisease
4
8
695
Javi del Cid retweeted
Estudio en frentamiento del paciente con hiperferritinemia (2026) #MedEd #MedTwitter #MedX doi.org/10.1111/ejh.70285 medicina-interna.org
2
84
242
9,694
NEW RESEARCH—Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study bit.ly/4whjqCF Plus, linked Comment bit.ly/4bzCKUb
1
13
28
1,936
Javi del Cid retweeted
Neuropathy 👇
One of my missions is to make Peripheral Neuropathies more understandable for non-experts. Recognizing that physicians often find PNs challenging, especially in the hospital setting, I collaborated with @MayoClinicNeuro Neuromuscular hospitalists, @ReeceHass and @SantilliAshley, and my former NM co-fellow #JMartinezThompson to develop an engaging infographic that simplifies how to approach neuropathies leading to hospitalization. The incredible artistic skills and creativity of @ReeceHass truly brought this project to life, exceeding all expectations. We hope you find this helpful. neurology.org/doi/pdf/10.121…
1
8
43
3,581
New content online: Advances in the treatment of eosinophilic granulomatosis with polyangiitis dlvr.it/TTrl8c
1
60
2
116
24,649